Dasatinib as a Bone-Modifying Agent: Anabolic and Anti-Resorptive Effects

BACKGROUND: Bone loss, in malignant or non-malignant diseases, is caused by increased osteoclast resorption and/or reduced osteoblast bone formation, and is commonly associated with skeletal complications. Thus, there is a need to identify new agents capable of influencing bone remodeling. We aimed...

Descripción completa

Detalles Bibliográficos
Autores principales: Garcia-Gomez, Antonio, Ocio, Enrique M., Crusoe, Edvan, Santamaria, Carlos, Hernández-Campo, Pilar, Blanco, Juan F., Sanchez-Guijo, Fermin M., Hernández-Iglesias, Teresa, Briñón, Jesús G., Fisac-Herrero, Rosa M., Lee, Francis Y., Pandiella, Atanasio, San Miguel, Jesús F., Garayoa, Mercedes
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3335111/
https://www.ncbi.nlm.nih.gov/pubmed/22539950
http://dx.doi.org/10.1371/journal.pone.0034914

Ejemplares similares

Ejemplares similares